The FDA has cleared Bellicum Pharmaceuticals’ (NASDAQ:BLCM) investigational new drug application (IND) for BPX-603.
BPX-603 is a GoCAR-T product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2).
The company plans to initiate Phase 1/2 trial later this year.
BPX-603 is the company’s first dual-switch
GoCAR-T product, which incorporates both the company’s iMC activation
and CaspaCIDe safety switch technologies.
https://seekingalpha.com/news/3582963-bellicum-pharma-on-go-mid-stage-study-of-bpxminus-603-for-her2-solid-tumors
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.